achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.
Company profile
Ticker
ACHL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Achilles Therapeutics Ltd
SEC CIK
ACHL stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
4 Apr 24
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
13 Nov 23
6-K
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
22 Sep 23
6-K
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
4 Aug 23
6-K
Current report (foreign)
29 Jun 23
6-K
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
10 May 23
6-K
Current report (foreign)
24 Apr 23
S-8
Registration of securities for employees
8 Mar 23
20-F
2022 FY
Annual report (foreign)
7 Mar 23
Latest ownership filings
SC 13G/A
Artal International S.C.A.
29 Mar 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Syncona Portfolio Ltd
13 Feb 24
144
Notice of proposed sale of securities
1 Feb 24
144
Notice of proposed sale of securities
1 Nov 23
144
Notice of proposed sale of securities
17 Aug 23
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
Redmile Group, LLC
14 Feb 23
SC 13G/A
Artal International S.C.A.
13 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
55.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 1 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 16.13 bn |
Total shares | 22.04 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Syncona Portfolio | 11.09 mm | $10.48 bn |
Baker Bros. Advisors | 2.56 mm | $2.42 bn |
Artal | 2.26 mm | $2.13 mm |
Artal International S.C.A. | 2.26 mm | $0.00 |
Redmile | 1.61 mm | $1.52 bn |
Point72 Asset Management | 1.41 mm | $1.34 bn |
Renaissance Technologies | 449.73 k | $425.00 k |
EDENTREE ASSET MANAGEMENT | 100.00 k | $94.52 mm |
Forefront Analytics | 74.77 k | $70.67 mm |
MS Morgan Stanley | 72.75 k | $68.77 mm |
News
Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $6
5 Apr 24
Piper Sandler Downgrades Achilles Therapeutics to Neutral, Lowers Price Target to $2
5 Apr 24
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
4 Apr 24
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
4 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
4 Apr 24
Press releases
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
4 Apr 24
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
4 Apr 24